Limits...
Gelfoam embolization or 125I seed implantation may be a more effective treatment than surgical treatment for giant benign sacral neurogenic tumors.

Ma X, Wei S, Yang C, Hua Y, Shen J, Cai Z - World J Surg Oncol (2015)

Bottom Line: Nineteen cases received surgical resection, and five cases received non-surgical treatment.In surgical group, patients with type III sacral tumor had received a combined anterior-posterior approach and patients with type IV were treated with simple anterior approach.Patients in non-surgical group were followed up for 2-8 years.

View Article: PubMed Central - PubMed

Affiliation: Department of Orthopedics, Tongji University, Shanghai Tenth People's Hospital, 301 Yanchang Rd, Shanghai, 200072, China. XiaojunMaxjm@163.com.

ABSTRACT

Background: The goal of the present study was to assess the effects of computed tomography (CT)-guided iodine-125 (125I) seed implantation or gelatin sponge particle (GSP) embolization on patients with giant benign sacral neurogenic tumors.

Methods: A total of 24 cases with giant sacral neurogenic tumor were performed in a retrospective study between 2000 and 2012. Nineteen cases received surgical resection, and five cases received non-surgical treatment. In surgical group, patients with type III sacral tumor had received a combined anterior-posterior approach and patients with type IV were treated with simple anterior approach. In non-surgical group, CT-guided 125I seed implantation or GSP embolization was applied to occlude vessels. Besides, CT scanning or magnetic resonance imaging was used to assess the size and development of tumors.

Results: Two of the five patients were treated three times with GSP embolization, one had received GSP embolization combined with CT-guided 125I seed implantation, one case did not receive any treatment, and one patient was lost to follow-up. Patients in non-surgical group were followed up for 2-8 years.

Conclusions: Our study suggested that CT-guided 125I seed implantation or GSP embolization treatment is very useful to slow down the development of giant benign sacral neurogenic tumors.

No MeSH data available.


Related in: MedlinePlus

The computerized tomography (CT) scans of patient B before and after gelatin sponge particle (GSPs) implantation. Patient B received thrice of GSPs implantation in July 2011, April 2012, and December 2013, respectively. a, b The CT scans taken in February 2011; c, d: The CT scans taken in January 2014
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4536730&req=5

Fig2: The computerized tomography (CT) scans of patient B before and after gelatin sponge particle (GSPs) implantation. Patient B received thrice of GSPs implantation in July 2011, April 2012, and December 2013, respectively. a, b The CT scans taken in February 2011; c, d: The CT scans taken in January 2014

Mentions: Patient B (51 years old, male), with low back pain and sacrococcygeal pain, was diagnosed with sacral neurofibroma. The primary tumor size was 12 × 10 × 8 cm. The patient had received three times gelfoam embolization in July 2011, April 2012, and December 2013, respectively. Three years of follow-up indicated that the development of tumor (13 × 10 × 8 cm) was slow-growing after treatment (Fig. 2).Fig. 2


Gelfoam embolization or 125I seed implantation may be a more effective treatment than surgical treatment for giant benign sacral neurogenic tumors.

Ma X, Wei S, Yang C, Hua Y, Shen J, Cai Z - World J Surg Oncol (2015)

The computerized tomography (CT) scans of patient B before and after gelatin sponge particle (GSPs) implantation. Patient B received thrice of GSPs implantation in July 2011, April 2012, and December 2013, respectively. a, b The CT scans taken in February 2011; c, d: The CT scans taken in January 2014
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4536730&req=5

Fig2: The computerized tomography (CT) scans of patient B before and after gelatin sponge particle (GSPs) implantation. Patient B received thrice of GSPs implantation in July 2011, April 2012, and December 2013, respectively. a, b The CT scans taken in February 2011; c, d: The CT scans taken in January 2014
Mentions: Patient B (51 years old, male), with low back pain and sacrococcygeal pain, was diagnosed with sacral neurofibroma. The primary tumor size was 12 × 10 × 8 cm. The patient had received three times gelfoam embolization in July 2011, April 2012, and December 2013, respectively. Three years of follow-up indicated that the development of tumor (13 × 10 × 8 cm) was slow-growing after treatment (Fig. 2).Fig. 2

Bottom Line: Nineteen cases received surgical resection, and five cases received non-surgical treatment.In surgical group, patients with type III sacral tumor had received a combined anterior-posterior approach and patients with type IV were treated with simple anterior approach.Patients in non-surgical group were followed up for 2-8 years.

View Article: PubMed Central - PubMed

Affiliation: Department of Orthopedics, Tongji University, Shanghai Tenth People's Hospital, 301 Yanchang Rd, Shanghai, 200072, China. XiaojunMaxjm@163.com.

ABSTRACT

Background: The goal of the present study was to assess the effects of computed tomography (CT)-guided iodine-125 (125I) seed implantation or gelatin sponge particle (GSP) embolization on patients with giant benign sacral neurogenic tumors.

Methods: A total of 24 cases with giant sacral neurogenic tumor were performed in a retrospective study between 2000 and 2012. Nineteen cases received surgical resection, and five cases received non-surgical treatment. In surgical group, patients with type III sacral tumor had received a combined anterior-posterior approach and patients with type IV were treated with simple anterior approach. In non-surgical group, CT-guided 125I seed implantation or GSP embolization was applied to occlude vessels. Besides, CT scanning or magnetic resonance imaging was used to assess the size and development of tumors.

Results: Two of the five patients were treated three times with GSP embolization, one had received GSP embolization combined with CT-guided 125I seed implantation, one case did not receive any treatment, and one patient was lost to follow-up. Patients in non-surgical group were followed up for 2-8 years.

Conclusions: Our study suggested that CT-guided 125I seed implantation or GSP embolization treatment is very useful to slow down the development of giant benign sacral neurogenic tumors.

No MeSH data available.


Related in: MedlinePlus